News

Zepbound Patients Fear Losing Coverage After CVS Deal for Wegovy
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
NVO’s Mixed Q1 Results, Files for Oral GLP-1 Drug for Obesity
Despite lower-than-expected first-quarter revenues and a guidance cut for 2025, NVO stock price rose post its earnings ...
Zacks Investment Research on MSN5h
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...
pharmaphorum18h
Lilly hit as PBM drops Zepbound, but retains Wegovy
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo Nordisk, after negotiating a price cut with the company, along with Novo ...
Reuters18h
Global Market Headlines | Breaking Stock Market News | Reuters
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., May 7, 2025. REUTERS/Brendan McDermid/File photo U.S. stocks rose on Thursday as investors cheered a new ...